Navigation Links
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy

tary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Helix disclaims responsibility for information contained in the Tu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... India , August 28, 2015 ... Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ... , Asia-Pacific , and Rest of the ... MarketsandMarkets, The global market for Eubiotics was valued at USD ... 7.05 Billion by 2020, at a CAGR of 7.4% from ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Fla., Dec. 2 Jupiter Medical Center ... into its imaging program, the new Signa HDx 1.5T MRI ... of the human body with increased speed, better resolution and ... for patients with renal dysfunction. This results in shorter ...
... , , NEW YORK, Dec. 2 ... five veteran attorneys, led by Neil H. Ekblom, LeClairRyan,s ... in the New York market. Mr. Ekblom, a former ... claims. , The New York team adds to an ...
Cached Medicine Technology:Jupiter Medical Center Announces New High-Definition MRI System 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 3
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... said one of two inventors from Miller Place, N.Y. "I specialize in manual ... and discomfort. In addition, it can be used for additional muscle dysfunction throughout ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... Dr. ... a mission. His mission is to increase acceptance of the chiropractic field in ... medications that further debilitate them. Although Chiropractic was made available to the VA ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed ... of unique footage that users can shrink and stretch in the Final Cut Pro ... can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... Socially isolated men may have increased levels of blood marker ... from Harvard School of Public Health say that it may ... to be socially connected. A well-connected man will have a ... connection to the immediate society like the workplace, or the ...
... cardiovascular diseases for better in as early as ... Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. ... Mediterranean type diet may bring about serious changes ... have a high risk of cardiovascular disease. ...
... employees may be less health conscious and may be spending ... ,New research suggests that working full time leads to a ... term. People who work full time have less time for ... games or sit in front of the computer. These seem ...
... a recent study researchers say cholesterol may be actually needed ... however researchers also say that too much of it could ... arteries, where it builds up as plaque and can cause ... ACAT2 may be to blame for the build-up. ACAT2 is ...
... cohosh, an herb, is often used for treatment of menopausal ... chemotherapy taken for breast cancer the results may be altered. ... report have said that alternative medication or self medication taken ... to chemotherapy. Most of the time doctors are not even ...
... have been able to successfully diagnose autism in infants ... to systematically document early signs of autism in children ... confirmed the diagnosis in a follow up study, till ... involved development of computerized visual orienting task, standardized measures ...
Cached Medicine News:
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
Medicine Products: